Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta

Core Insights - BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial for its cell therapy BT-101, targeting Osteogenesis imperfecta, at the 15th International Conference on Osteogenesis imperfecta in Hong Kong [1][2] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101 as a stem cell therapy for infants with Osteogenesis imperfecta, a condition leading to fragile bones and frequent fractures [2] - Karolinska Development AB holds a 14% ownership stake in BOOST Pharma, indicating its investment in innovative medical solutions [4] Clinical Trial Results - Long-term results from the BOOSTB4 trial show that over 50% of treated patients did not experience any bone fractures in the second year after the last dose [3] - The previously reported 70% reduction in fractures during the first year was maintained and improved, leading to an overall reduction of nearly 78% compared to the pre-treatment period [3] Therapeutic Potential - The results from BOOST Pharma suggest that BT-101 has a robust therapeutic effect and potential as a disease-modifying treatment in a field with significant medical need and no adequate existing treatments [4]